2 Stocks Make It On Today's Healthcare & Biotech Stock Watchlist
Powered by HealthTechMovers.com
We added 2 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Celldex, CLDX
Summary: CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
- Last Price: $46.52
- Price Change: -$0.07, -0.15%
- Yearly Gain: 61.49%
- Market Cap: $2.20B
- P/E Ratio: -20.564
Here are 3rd party ratings for CLDX:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 33% (84 out of 251)
What is the sentiment on the street regarding Celldex ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Neutral
- Investor Sentiment: Positive
- Hedge Fund signal: Neutral
If you are interested in CLDX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CLDX before you decide to make any investment.
Click here for chart >>
Rain Therapeutics, RAIN
Summary: Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc., formerly known as Rain Therapeutics Inc., is based in NEWARK, Calif.
- Last Price: $9.64
- Price Change: -$0.21, -2.13%
- Yearly Gain: 6.60%
- Market Cap: $333.49M
- P/E Ratio: -3.677
Here are 3rd party ratings for RAIN:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 33% (84 out of 251)
What is the sentiment on the street regarding Rain Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in RAIN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on RAIN before you decide to make any investment.
Click here for chart >>
Thanks for reading!